|
1
|
Wang H, Yu X, Guo J, Ma S, Liu Y, Hu Y, Li
J, Song Y and Zou Z: Burden of cardiovascular disease among the
Western Pacific region and its association with human resources for
health, 1990–2021: A systematic analysis of the global burden of
disease study 2021. Lancet Reg Health West Pac.
51:1011952024.PubMed/NCBI
|
|
2
|
Ji C, Ge X, Zhang J and Tong H: The stroke
burden in china and its long-term trends: Insights from the global
burden of disease (GBD) study 1990–2021. Nutr Metab Cardiovasc Dis.
35:1038482025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fu Y, Liu Q, Anrather J and Shi FD: Immune
interventions in stroke. Nat Rev Neurol. 11:524–535. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li M, Li Z, Yao Y, Jin WN, Wood K, Liu Q,
Shi FD and Hao J: Astrocyte-derived interleukin-15 exacerbates
ischemic brain injury via propagation of cellular immunity. Proc
Natl Acad Sci USA. 114:E396–E405. 2017.PubMed/NCBI
|
|
5
|
Zhang F, Yan C, Wei C, Yao Y, Ma X, Gong
Z, Liu S, Zang D, Chen J, Shi FD and Hao J: Vinpocetine inhibits
NF-κB-dependent inflammation in acute ischemic stroke patients.
Transl Stroke Res. 9:174–184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Endres M, Moro MA, Nolte CH, Dames C,
Buckwalter MS and Meisel A: Immune pathways in etiology, acute
phase, and chronic sequelae of ischemic stroke. Circ Res.
130:1167–1186. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zietz A, Gorey S, Kelly PJ, Katan M and
McCabe JJ: Targeting inflammation to reduce recurrent stroke. Int J
Stroke. 19:379–387. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pawluk H, Woźniak A, Tafelska-Kaczmarek A,
Kosinska A, Pawluk M, Sergot K, Grochowalska R and Kołodziejska R:
The role of IL-6 in ischemic stroke. Biomolecules. 15:4702025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui P, McCullough LD and Hao J: Brain to
periphery in acute ischemic stroke: Mechanisms and clinical
significance. Front Neuroendocrinol. 63:1009322021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stanzione R, Forte M, Cotugno M, Bianchi
F, Marchitti S and Rubattu S: Role of DAMPs and of leukocytes
infiltration in ischemic stroke: Insights from animal models and
translation to the human disease. Cell Mol Neurobiol. 42:545–556.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumari S, Dhapola R, Sharma P, Nagar P,
Medhi B and HariKrishnaReddy D: The impact of cytokines in
neuroinflammation-mediated stroke. Cytokine Growth Factor Rev.
78:105–119. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai TW, Zhang S and Wang YT:
Excitotoxicity and stroke: Identifying novel targets for
neuroprotection. Prog Neurobiol. 115:157–188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang C, Wang C, Zhang Y, Xue L, Li Y, Ju C
and Zhang C: Recognition, intervention, and monitoring of
neutrophils in acute ischemic stroke. Nano Lett. 19:4470–4477.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dhanesha N, Patel RB, Doddapattar P,
Ghatge M, Flora GD, Jain M, Thedens D, Olalde H, Kumskova M, Leira
EC and Chauhan AK: PKM2 promotes neutrophil activation and cerebral
thromboinflammation: Therapeutic implications for ischemic stroke.
Blood. 139:1234–1245. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi K, Tian DC, Li ZG, Ducruet AF, Lawton
MT and Shi FD: Global brain inflammation in stroke. Lancet Neurol.
18:1058–1066. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iadecola C, Buckwalter MS and Anrather J:
Immune responses to stroke: Mechanisms, modulation, and therapeutic
potential. J Clin Invest. 130:2777–2788. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Q, Tang XN and Yenari MA: The
inflammatory response in stroke. J Neuroimmunol. 184:53–68. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jayaraj RL, Azimullah S, Beiram R, Jalal
FY and Rosenberg GA: Neuroinflammation: Friend and foe for ischemic
stroke. J Neuroinflammation. 16:1422019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu D, Chen WQ, Wang YP, Duan WY, Guo L,
Wang L, Liu L, Xu AD and Wang YJ: Scientific Statements on Brain
Cytoprotection in Ischemic Stroke—A Scientific Statement from the
Chinese Stroke Association. Chin J Stroke. 19:938–55. 2024.(In
Chinese).
|
|
20
|
Tanaka T and Kishimoto T: The biology and
medical implications of interleukin-6. Cancer Immunol Res.
2:288–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taher MY, Davies DM and Maher J: The role
of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc
Trans. 46:1449–1462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scheller J, Chalaris A, Schmidt-Arras D
and Rose-John S: The pro- and anti-inflammatory properties of the
cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Montgomery A, Tam F, Gursche C, Cheneval
C, Besler K, Enns W, Manku S, Rey K, Hanson PJ, Rose-John S, et al:
Overlapping and distinct biological effects of IL-6 classic and
trans-signaling in vascular endothelial cells. Am J Physiol Cell
Physiol. 320:C554–C565. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mihara M, Hashizume M, Yoshida H, Suzuki M
and Shiina M: IL-6/IL-6 receptor system and its role in
physiological and pathological conditions. Clin Sci (Lond).
122:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heo TH, Wahler J and Suh N: Potential
therapeutic implications of IL-6/IL-6R/gp130-targeting agents in
breast cancer. Oncotarget. 7:15460–15473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
März P, Cheng JG, Gadient RA, Patterson
PH, Stoyan T, Otten U and Rose-John S: Sympathetic neurons can
produce and respond to interleukin 6. Proc Natl Acad Sci USA.
95:3251–3256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heink S, Yogev N, Garbers C, Herwerth M,
Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K,
Bartsch HS, et al: Trans-presentation of IL-6 by dendritic cells is
required for the priming of pathogenic T(H)17 cells. Nat Immunol.
18:74–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gu Y, He M, Zhou X, Liu J, Hou N, Bin T,
Zhang Y, Li T and Chen J: Endogenous IL-6 of mesenchymal stem cell
improves behavioral outcome of hypoxic-ischemic brain damage
neonatal rats by supressing apoptosis in astrocyte. Sci Rep.
6:185872016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu H, Hu S, Li Y, Sun Y, Xiong X, Hu X,
Chen J and Qiu S: Interleukins and ischemic stroke. Front Immunol.
13:8284472022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pacinella G, Ciaccio AM, Casuccio A,
Daidone M, Pecoraro R, Di Bona D, Del Cuore A, Puleo MG, Di
Raimondo D, Di Chiara T, et al: Genetic polymorphisms and cytokine
levels in ischemic stroke: Associations with subtypes and
prognosis. Expert Rev Clin Immunol. 21:961–976. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang X, Zhang M, Wang J and Hu F:
Association between interleukin-6 levels and stroke: A systematic
review and meta-analysis. J Int Med Res. 52:30006052412746262024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sanderson TH, Reynolds CA, Kumar R,
Przyklenk K and Hüttemann M: Molecular mechanisms of
ischemia-reperfusion injury in brain: Pivotal role of the
mitochondrial membrane potential in reactive oxygen species
generation. Mol Neurobiol. 47:9–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shirley R, Ord EN and Work LM: Oxidative
stress and the use of antioxidants in stroke. Antioxidants (Basel).
3:472–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dong X, Wu D, Zhang Y, Jia L, Pan X, Sun J
and Pan LL: Cathelicidin modulates vascular smooth muscle cell
phenotypic switching through ROS/IL-6 pathway. Antioxidants
(Basel). 9:4912020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan M, Sun Z, Zhang S, Yang G, Jiang X,
Wang G, Li R, Wang Q and Tian X: SOCS modulates JAK-STAT pathway as
a novel target to mediate the occurrence of neuroinflammation:
Molecular details and treatment options. Brain Res Bull.
213:1109882024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang SR, Li CT, Yang Y and Zhang LH:
Oxidative stress, inflammation and autophagy in cerebral ischemic
injury: mechanisms and therapeutic strategies. Chin J Pharmacol
Toxicol. 32:651–660. 2018.(In Chinese).
|
|
37
|
Kang S and Kishimoto T: Interplay between
interleukin-6 signaling and the vascular endothelium in cytokine
storms. Exp Mol Med. 53:1116–1123. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Henein MY, Vancheri S, Longo G and
Vancheri F: The role of inflammation in cardiovascular disease. Int
J Mol Sci. 23:129062022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Webb CE, Vautrinot J and Hers I: IL-6 as a
mediator of platelet hyper-responsiveness. Cells. 14:7662025.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang W, Tian T, Gong SX, Huang WQ, Zhou
QY, Wang AP and Tian Y: Microglia-associated neuroinflammation is a
potential therapeutic target for ischemic stroke. Neural Regen Res.
16:6–11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Purroy F, Farré-Rodriguez J,
Mauri-Capdevila G, Vicente-Pascual M and Farré J: Basal IL-6 and
S100b levels are associated with infarct volume. Acta Neurol Scand.
144:517–523. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ohta M, Kihara T, Toriuchi K, Aoki H,
Iwaki S, Kakita H, Yamada Y and Aoyama M: IL-6 promotes cell
adhesion in human endothelial cells via microRNA-126-3p
suppression. Exp Cell Res. 393:1120942020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mo J, Chen Z, Wang M, Cheng A, Li J, Pan
Y, Jiang Y, Jing J, Wang Y, Pu Y and Li Z: Association between
interleukin-6 and multiple acute infarctions in symptomatic
intracranial atherosclerotic disease. Curr Neurovasc Res.
21:292–299. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang X, Liao KH, Deng IB and Zhang LC:
Knockdown of interleukin-6 plays a neuroprotective role against
hypoxia-ischemia in neonatal rats via inhibition of caspase 3 and
Bcl-2-associated X protein signaling pathway. Ibrain. 8:413–428.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhan L, Mu Z, Jiang H, Zhang S, Pang Y,
Jin H, Chen J, Jia C and Guo H: MiR-21-5p protects against ischemic
stroke by targeting IL-6R. Ann Transl Med. 11:1012023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Radak D, Resanovic I and Isenovic ER:
Changes in hypothalamus-pituitary-adrenal axis following transient
ischemic attack. Angiology. 65:723–732. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Crofford LJ, Kalogeras KT, Mastorakos G,
Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP and Wilder RL:
Circadian relationships between interleukin (IL)-6 and
hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to
cause sustained hypercortisolism in patients with early untreated
rheumatoid arthritis. J Clin Endocrinol Metab. 82:1279–1283. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hassamal S: Chronic stress,
neuroinflammation, and depression: An overview of
pathophysiological mechanisms and emerging anti-inflammatories.
Front Psychiatry. 14:11309892023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roy M, Collier B and Roy A:
Hypothalamic-pituitary-adrenal axis dysregulation among diabetic
outpatients. Psychiatry Res. 31:31–37. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim S, Park ES, Chen PR and Kim E:
Dysregulated hypothalamic-pituitary-adrenal axis is associated with
increased inflammation and worse outcomes after ischemic stroke in
diabetic mice. Front Immunol. 13:8648582022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kamtchum-Tatuene J, Saba L, Heldner MR,
Poorthuis MHF, de Borst GJ, Rundek T, Kakkos SK, Chaturvedi S,
Topakian R, Polak JF, et al: Interleukin-6 predicts carotid plaque
severity, vulnerability, and progression. Circ Res. 131:e22–e33.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mehta NN, deGoma E and Shapiro MD: IL-6
and cardiovascular risk: A narrative review. Curr Atheroscler Rep.
27:122024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lundin JI, Peters U, Hu Y, Ammous F,
Benjamin EJ, Bis JC, Brody JA, Cushman M, Fuller H, Gignoux C, et
al: Epigenetic mechanisms underlying variation of IL-6, a
well-established inflammation biomarker and risk factor for
cardiovascular disease. Atherosclerosis. 407:1202192025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kitagawa K, Toi S, Yoshizawa H, Sato Y and
Todo K: Association between serum levels of interleukin-6 and
stroke, cardiovascular events, and Alzheimer's disease dementia. J
Atheroscler Thromb. 32:1390–1399. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jenny NS, Callas PW, Judd SE, McClure LA,
Kissela B, Zakai NA and Cushman M: Inflammatory cytokines and
ischemic stroke risk: The REGARDS cohort. Neurology.
92:e2375–e2384. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Papadopoulos A, Palaiopanos K, Björkbacka
H, Peters A, de Lemos JA, Seshadri S, Dichgans M and Georgakis MK:
Circulating interleukin-6 levels and incident ischemic stroke: A
systematic review and meta-analysis of prospective studies.
Neurology. 98:e1002–e1012. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jiang Y and Fan T: IL-6 and stroke
recurrence in ischemic stroke. Biomark Med. 18:739–747. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xu J, Mo J, Zhang X, Chen Z, Pan Y, Yan H,
Meng X and Wang Y: Nontraditional risk factors for residual
recurrence risk in patients with ischemic stroke of different
etiologies. Cerebrovasc Dis. 51:630–638. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li J, Lin J, Pan Y, Wang M, Meng X, Li H,
Wang Y, Zhao X, Qin H, Liu L, et al: Interleukin-6 and YKL-40
predicted recurrent stroke after ischemic stroke or TIA: analysis
of 6 inflammation biomarkers in a prospective cohort study. J
Neuroinflammation. 19:1312022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
McCabe JJ, Harris K, Walsh C, Gorey S,
Arnold M, De Marchis GM, Hervella P, Iglesias-Rey R, Jern C, Katan
M, et al: Interleukin-6, C-reactive protein, and vascular
recurrence after stroke with and without atherosclerosis. Stroke.
56:2588–2596. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Georgakis MK, Malik R, Gill D,
Franceschini N, Sudlow CLM and Dichgans M; INVENT Consortium,
CHARGE Inflammation Working Group, : Interleukin-6 signaling
effects on ischemic stroke and other cardiovascular outcomes: A
mendelian randomization study. Circ Genom Precis Med.
13:e0028722020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang L, Omarov M, Xu L, deGoma E,
Natarajan P and Georgakis MK: IL6 genetic perturbation mimicking
IL-6 inhibition is associated with lower cardiometabolic risk. Nat
Cardiovasc Res. 4:1172–1186. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cui JJ, Zhang CZ, Zhu B, Xu ZP and Liu YY:
Serum miR-21-5p, IL-6, and IL-8 Expression Levels and Predictive
Model Construction in Patients with Cerebral Infarction. Chin J
Gerontology. 43:4103–4106. 2023.(In Chinese).
|
|
64
|
Kowalski RG, Ledreux A, Violette JE,
Paustian W, Sillau S, Thompson JA, Neumann RT, Ornelas D, Monte AA,
Dylla L, et al: Circulating interleukin-6 levels and timing of
acute ischemic stroke onset. Ann Clin Transl Neurol. 12:1926–1931.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Su JH, Luo MY, Liang N, Gong SX, Chen W,
Huang WQ, Tian Y and Wang AP: Interleukin-6: A novel target for
cardio-cerebrovascular diseases. Front Pharmacol. 12:7450612021.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mosarrezaii A, Amiri-Nikpour MR, Mehryar
HR, Choobi Anzali B, Nourooz-Zadeh S, Babaei S and Farrokhi H:
Investigating the relationship between interleukin-6 serum levels
and outcome in acute ischemic CVA. Brain Behav. 10:e016682020.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Alfieri DF, Lehmann MF, Flauzino T, de
Araújo MCM, Pivoto N, Tirolla RM, Simão ANC, Maes M and Reiche EMV:
Immune-inflammatory, metabolic, oxidative, and nitrosative stress
biomarkers predict acute ischemic stroke and short-term outcome.
Neurotox Res. 38:330–343. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li X, Lin S, Chen X, Huang W, Li Q, Zhang
H, Chen X, Yang S, Jin K and Shao B: The prognostic value of serum
cytokines in patients with acute ischemic stroke. Aging Dis.
10:544–556. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Jia WL, Jiang YY, Jiang Y, Meng X, Li H,
Zhao XQ, Wang YL, Wang YJ, Gu HQ and Li ZX: Associations between
admission levels of multiple biomarkers and subsequent worse
outcomes in acute ischemic stroke patients. J Cereb Blood Flow
Metab. 44:742–756. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gu HQ, Yang KX, Li JJ, Lin JX, Jing J,
Xiong YY, Zhao XQ, Wang YL, Liu LP, Meng X, et al: Mediation effect
of stroke recurrence in the association between post-stroke
interleukin-6 and functional disability. CNS Neurosci Ther.
29:3579–3587. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dargazanli C, Blaquière M, Moynier M, de
Bock F, Labreuche J, Ter Schiphorst A, Derraz I, Radu RA, Gascou G,
Lefevre PH, et al: Inflammation biomarkers in the intracranial
blood are associated with outcome in patients with ischemic stroke.
J Neurointerv Surg. 17:159–166. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pawluk H, Kołodziejska R, Grześk G,
Kozakiewicz M, Woźniak A, Pawluk M, Kosinska A, Grześk M, Wojtasik
J and Kozera G: Selected mediators of inflammation in patients with
acute ischemic stroke. Int J Mol Sci. 23:106142022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hervella P, Rodríguez-Castro E,
Rodríguez-Yáñez M, Arias S, Santamaría-Cadavid M, López-Dequidt I,
Estany-Gestal A, Maqueda E, López-Loureiro I, Sobrino T, et al:
Intra- and extra-hospital improvement in ischemic stroke patients:
Influence of reperfusion therapy and molecular mechanisms. Sci Rep.
10:35132020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Băcilă CI, Vlădoiu MG, Văleanu M, Moga DF
and Pumnea PM: The role of IL-6 and TNF-alpha biomarkers in
predicting disability outcomes in acute ischemic stroke patients.
Life Basel). 15:472025. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yi L, Li ZX, Jiang YY, Jiang Y, Meng X, Li
H, Zhao XQ, Wang YL, Liu LP, Wang YJ and Gu HQ: Inflammatory marker
profiles and in-hospital neurological deterioration in patients
with acute minor ischemic stroke. CNS Neurosci Ther. 30:e146482024.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sabir Rashid A, Huang-Link Y, Johnsson M,
Wetterhäll S and Gauffin H: Predictors of early neurological
deterioration and functional outcome in acute ischemic stroke: The
importance of large artery disease, hyperglycemia and inflammatory
blood biomarkers. Neuropsychiatr Dis Treat. 18:1993–2002. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Deng QW, Huang S, Li S, Zhai Q, Zhang Q,
Wang ZJ, Chen WX, Sun H, Lu M and Zhou J: Inflammatory factors as
potential markers of early neurological deterioration in acute
ischemic stroke patients receiving endovascular therapy-the AISRNA
study. J Inflamm Res. 14:4399–4407. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Grebenciucova E and VanHaerents S:
Interleukin 6: At the interface of human health and disease. Front
Immunol. 14:12555332023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hall C, Nguyen DT, Mendoza K, Tan C and
Chauhan A: Inhibition of IL-6 trans-signaling promotes post-stroke
functional recovery in a sex and dose-dependent manner. J
Neuroinflammation. 22:522025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hudobenko J, Chauhan A and McCullough L:
Abstract 128: Amelioration of ischemic stroke damage through
inhibition of interleukin-6 signaling with tocilizumab requires sex
specific dosing. Stroke. 50 (Suppl 1):A1282019. View Article : Google Scholar
|
|
81
|
Schuett H, Oestreich R, Waetzig GH, Annema
W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D,
Kempf T, et al: Transsignaling of interleukin-6 crucially
contributes to atherosclerosis in mice. Arterioscler Thromb Vasc
Biol. 32:281–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ministrini S, Liberale L, Puspitasari YM,
Han J, Kirmes K, Unkelbach LP, Tirandi A, Niederberger R, Bengs S,
Beer JH, et al: Direct interleukin-6 inhibition blunts arterial
thrombosis by reducing collagen-mediated platelet activation.
Arterioscler Thromb Vasc Biol. 45:1432–1439. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chu X, Ma Z, Liu Y, Sun J, Wang N, Li C,
Feng X, Li J, Wang B, Zhou C, et al: IRIS, a randomised,
double-blind, placebo-controlled trial of interleukin-6 receptor
inhibition undergoing endovascular treatment in acute anterior
circulation ischaemic stroke: Study rationale and design. Stroke
Vasc Neurol. 10:514–519. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Huse C, Anstensrud AK, Michelsen AE,
Ueland T, Broch K, Woxholt S, Yang K, Sharma K, Tøllefsen IM, Bendz
B, et al: Interleukin-6 inhibition in ST-elevation myocardial
infarction: Immune cell profile in the randomised ASSAIL-MI trial.
EBioMedicine. 80:1040132022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ridker PM, Devalaraja M, Baeres FMM,
Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj
D, et al: IL-6 inhibition with ziltivekimab in patients at high
atherosclerotic risk (RESCUE): A double-blind, randomised,
placebo-controlled, phase 2 trial. Lancet. 397:2060–2069. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
GlobeNewswire, . Tourmaline Bio Announces
Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial
Evaluating Pacibekitug in Patients with Elevated High-Sensitivity
C-reactive Protein and Chronic Kidney Disease. Tourmaline Inc.;
https://www.globenewswire.com/news-release/2025/05/20/3084742/0/en/Tourmaline-Bio-Announces-Positive-Topline-Results-from-the-Ongoing-Phase-2-TRANQUILITY-Trial-Evaluating-Pacibekitug-in-Patients-with-Elevated-High-Sensitivity-C-reactive-Protein-an.htmlAugust
7–2025
|
|
87
|
Ridker PM: From RESCUE to ZEUS: will
interleukin-6 inhibition with ziltivekimab prove effective for
cardiovascular event reduction? Cardiovasc Res. 117:e138–e140.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ridker PM and Rane M: Interleukin-6
signaling and anti-interleukin-6 therapeutics in cardiovascular
disease. Circ Res. 128:1728–1746. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Rose-John S, Jenkins BJ, Garbers C, Moll
JM and Scheller J: Targeting IL-6 trans-signalling: Past, present
and future prospects. Nat Rev Immunol. 23:666–681. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Jostock T, Müllberg J, Ozbek S, Atreya R,
Blinn G, Voltz N, Fischer M, Neurath MF and Rose-John S: Soluble
gp130 is the natural inhibitor of soluble interleukin-6 receptor
transsignaling responses. Eur J Biochem. 268:160–167. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Weiss A and Ding Y: Beyond reperfusion:
Adjunctive therapies targeting inflammation, edema, and blood-brain
barrier dysfunction in ischemic stroke. Cerebrovasc Dis. 1–10.
2025.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Acalovschi D, Wiest T, Hartmann M, Farahmi
M, Mansmann U, Auffarth GU, Grau AJ, Green FR, Grond-Ginsbach C and
Schwaninger M: Multiple levels of regulation of the interleukin-6
system in stroke. Stroke. 34:1864–1869. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ziegler L, Wallén H, Aspberg S, de Faire U
and Gigante B: IL6 trans-signaling associates with ischemic stroke
but not with atrial fibrillation. BMC Neurol. 21:3062021.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ridker PM, Libby P, MacFadyen JG, Thuren
T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM and
Glynn RJ: Modulation of the interleukin-6 signalling pathway and
incidence rates of atherosclerotic events and all-cause mortality:
Analyses from the canakinumab anti-inflammatory thrombosis outcomes
study (CANTOS). Eur Heart J. 39:3499–3507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhu S, Pan W, Yao Y and Shi K: The
efficacy of colchicine compared to placebo for preventing ischemic
stroke among individuals with established atherosclerotic
cardiovascular diseases: A systematic review and meta-analysis.
Scand Cardiovasc J. 59:24411122025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Fiolet ATL, Poorthuis MHF, Opstal TSJ,
Amarenco P, Boczar KE, Buysschaert I, Budgeon C, Chan NC, Cornel
JH, Jolly SS, et al: Colchicine for secondary prevention of
ischaemic stroke and atherosclerotic events: A meta-analysis of
randomised trials. EClinicalMedicine. 76:1028352024. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Shi K, Zou M, Jia DM, Shi S, Yang X, Liu
Q, Dong JF, Sheth KN, Wang X and Shi FD: tPA mobilizes immune cells
that exacerbate hemorrhagic transformation in stroke. Circ Res.
128:62–75. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang H, Tian X, Liao Z, Yue X, Sun L, Li
X, Zou M and Ding J: Inflammatory biomarkers may be associated with
poor outcomes after mechanical thrombectomy. Thromb J. 22:582024.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Jafari M, Katlowitz K, De la Garza C,
Sellers A, Moore S, Hall H, Desai A, Singh V and Damani R: Impact
of systemic inflammatory response syndrome on acute ischemic stroke
patients treated with mechanical thrombectomy. J Neurol Sci.
430:1199882021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Jia Y, Zhang K, Shi M, Guo D, Yang P, Bu
X, Chen J, Wang A, Xu T, He J, et al: Associations of rheumatoid
factor, rheumatoid arthritis, and interleukin-6 inhibitor with the
prognosis of ischemic stroke: A prospective multicenter cohort
study and mendelian randomization analysis. Transl Stroke Res.
15:750–760. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Scheller J and Rose-John S: The
interleukin 6 pathway and atherosclerosis. Lancet. 380:3382012.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang M, Bai Y, Wang Y, Cui H, Tang M,
Wang L, Wang X and Gu D: Cumulative evidence for associations
between genetic variants in interleukin 6 receptor gene and human
diseases and phenotypes. Front Immunol. 13:8607032022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Georgakis MK, Malik R, Li X, Gill D, Levin
MG, Vy HMT, Judy R, Ritchie M, Verma SS; Regeneron Genetics Center,
; et al: Genetically downregulated interleukin-6 signaling is
associated with a favorable cardiometabolic profile: A phenome-wide
association study. Circulation. 143:1177–1780. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Said EA, Al-Reesi I, Al-Shizawi N, Jaju S,
Al-Balushi MS, Koh CY, Al-Jabri AA and Jeyaseelan L: Defining IL-6
levels in healthy individuals: A meta-analysis. J Med Virol.
93:3915–3924. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Docherty S, Harley R, McAuley JJ, Crowe
LAN, Pedret C, Kirwan PD, Siebert S and Millar NL: The effect of
exercise on cytokines: Implications for musculoskeletal health: A
narrative review. BMC Sports Sci Med Rehabil. 14:52022. View Article : Google Scholar : PubMed/NCBI
|
